1. Search Result
Search Result
Results for "

a-B

" in MedChemExpress (MCE) Product Catalog:

108

Inhibitors & Agonists

5

Fluorescent Dye

30

Biochemical Assay Reagents

6

Peptides

13

Inhibitory Antibodies

10

Natural
Products

19

Recombinant Proteins

3

Isotope-Labeled Compounds

6

Antibodies

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148348

    HBV Infection
    AB-836 is an orally active HBV capsid inhibitor. AB-836 inhibits viral replication by interacting with HBV core protein .
    AB-836
  • HY-148768

    HBV Inflammation/Immunology
    AB-506 is an orally active inhibitor of HBV replication targeting the viral core protein. AB-506 can bind to HBV core protein, accelerate capsid assembly and inhibit HBV pgRNA encapsidation. AB-506 can be used in chronic hepatitis B (CHB) research .
    AB-506
  • HY-118894

    Others
    AB-182 is an aziridine derivative and antitumor agent.AB-182 shows synergistic antitumor effects in conjunction with x-irradiation. Intermediate hydrolysis products of AB-182 may block the repair of x-irradiation-induced breaks in the DNA strands by phosphorylating their free 3'-OH end groups.
    AB182
  • HY-120316

    Parasite Infection
    AB3127-C is an anti-mite agent that can be isolated from Streptomyces platensis AB3217. AB3127-C exerts a protection coefficient of 90% at a concentration of 100 μg/mL .
    AB3127-C
  • HY-132603A

    HBV Small Interfering RNA (siRNA) Infection
    AB-729 sodium is a siRNA specifically designed to inhibit viral replication and reduces HBV antigens . AB-729 conjugates to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes uptake into hepatocytes via the asialoglycoprotein receptor (ASGR).
    AB-729 sodium
  • HY-163149

    HBV Infection
    AB-452, a Dihydroquinolizinone (DHQ) analogue, is a potent and orally active HBV RNA destabilizer. AB-452 inhibits PAPD5/7 proteins in vitro with good in vivo efficacy in a chronic HBV mouse model .
    AB-452
  • HY-115826

    Others Cancer
    AB-163 is an alkylating agent with anti-tumor activity. AB-163 exerts LD50s of 198 (p.o.) and 159 (i.p.) mg/kg in ICR/Ha male mice and can be utilized in cancer research .
    AB-163
  • HY-149855

    Sigma Receptor Others
    AB10 is a selective S1R antagonist. AB10 with Ki of 10, 165 nM for S1R and S2R, respectively. AB10 reverses the effect of Capsaicin (HY-10448) caused pain in model .
    AB10
  • HY-117241

    Parasite Infection
    AB 3217-B is an analog of AB 3217-A and has anti-mite activity.
    AB 3217-B
  • HY-155332

    Bacterial Infection
    AB131 is a MSMEG 6649 and Rv2172c inhibitor (Kd: 0.16 and 0.02 μM respectively). AB131 can sensitize the antimycobacterial activity of the antitubercular agent .
    AB131
  • HY-149854

    Sigma Receptor Neurological Disease
    AB21 is a potent and selective S1R antagonist with Kis of 13, 102 nM for S1R and S2R. AB21 has the effect of reducing mechanical hypersensitivity .
    AB21
  • HY-149854B

    Sigma Receptor Neurological Disease
    AB21 hydrochloride is a potent and selective S1R antagonist with Kis of 13, 102 nM for S1R and S2R. AB21 hydrochloride has the effect of reducing mechanical hypersensitivity .
    AB21 hydrochloride
  • HY-162859

    Others Cancer
    AB25583 is a Polθ helicase (Polθ-hel) small molecule inhibitor, with an IC50 value of 6 nM. AB25583 selectively kills BRCA1/2 deficient cells and works in synergy with Olaparib (HY-10162) in cancer cells carrying pathogenic BRCA1/2 mutations. AB25583 can be used for tumor research .
    AB25583
  • HY-10209A
    Masitinib mesylate
    5 Publications Verification

    AB-1010 mesylate

    c-Kit PDGFR Src FGFR Apoptosis Cancer
    Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity .
    Masitinib mesylate
  • HY-19365
    AB-MECA
    1 Publications Verification

    Adenosine Receptor Neurological Disease
    AB-MECA is a high affinity A3 adenosine receptor agonist with a binding Ki of 430.5 nM for human A3 receptors in CHO cells. AB-MECA can enhance plasma histamine level .
    AB-MECA
  • HY-125286
    AB-680
    5+ Cited Publications

    CD73 Cancer
    AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity .
    AB-680
  • HY-149854A

    Sigma Receptor Neurological Disease
    AB21 oxalate is a potent and selective S1R antagonist with Kis of 13, 102 nM for S1R and S2R. AB21 oxalate has the effect of reducing mechanical hypersensitivity .
    AB21 oxalate
  • HY-117986

    Antibiotic AB3217A

    Parasite Infection
    AB 3217-A, an anti-mite substance, can be isolated from the fermentation broth of a streptomycete strain .
    AB 3217-A
  • HY-125286A

    CD73 Cancer
    AB-680 ammonium is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity .
    AB-680 ammonium
  • HY-116077

    Others Others
    AB 5046B is a chlorosis-inducing substance can be isolated from Nodulisporium sp .
    AB 5046B
  • HY-112142
    AB-423
    3 Publications Verification

    (R)-DVR-23

    HBV Infection
    AB-423 is an inhibitor of HBV capsid assembly, and potent inhibits HBV replication with EC50/EC90 of 0.08-0.27 μM/0.33-1.32 μM in cells.
    AB-423
  • HY-117980

    AB 132

    Others Cancer
    Meturedepa (AB 132) functions as a radiation sensitizer, enhancing the biological effects of radiation. When combined with suboptimal doses of X-ray radiation, this combined therapy achieves better outcomes in terms of tumor shrinkage compared to Meturedepa used alone. Meturedepa is applicable in the research of bronchogenic carcinoma .
    Meturedepa
  • HY-10209
    Masitinib
    5 Publications Verification

    AB1010

    c-Kit PDGFR Src FGFR FAK Apoptosis Cancer
    Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity .
    Masitinib
  • HY-P1698

    AB-103

    Bacterial CD28 Infection Inflammation/Immunology Cancer
    Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs) .
    Reltecimod
  • HY-P99047

    AB 0024; GS 6624

    Monoamine Oxidase Inflammation/Immunology Cancer
    Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab can be used for the research of primary sclerosing cholangitis (PSC) .
    Simtuzumab
  • HY-145594

    AB-291; DS-1001

    Isocitrate Dehydrogenase (IDH) Cancer
    Safusidenib (AB-291; DS-1001) is an orally bioavailable, selective mutant IDH1 inhibitor. Safusidenib strongly inhibits mutant IDH1 but not wild-type IDH1. Safusidenib impairs tumor activity in chondrosarcoma . Safusidenib exhibits activity against IDH1R132H, and IDH1R132C with IC50s of 15, and 130 nM in assays without any preincubation, respectively .
    Safusidenib
  • HY-129393
    Etrumadenant
    5+ Cited Publications

    AB928

    Adenosine Receptor Inflammation/Immunology Cancer
    Etrumadenant (AB928) is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. Etrumadenant relieves adenosine-mediated immune suppression. Etrumadenant has immunomodulatory and antitumor activities .
    Etrumadenant
  • HY-P1698B

    AB-103 TFA

    Bacterial CD28 Infection Inflammation/Immunology Cancer
    Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs) .
    Reltecimod TFA
  • HY-159644

    AB521

    HIF/HIF Prolyl-Hydroxylase Cancer
    Casdatifan
  • HY-113945

    Antibiotic Bacterial Infection
    Abbeymycin is an antibiotic derived from the actinobacterium Streptomyces sp. AB-999F-52. Abbeymycin is a specifically acting antibiotic with antimicrobial activity, primarily targeting anaerobic bacteria. Abbeymycin is employed in research concerning antibiotic discovery and screening .
    Abbeymycin
  • HY-D0402

    AB26

    Fluorescent Dye
    Acid black 26 is a black agent whose coloring effect can be removed by adsorbents such as zeolites.
    Acid black 26
  • HY-P99109

    GLS-010; AB-122; WBP-3055

    PD-1/PD-L1 Cancer
    Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
    Zimberelimab
  • HY-131003
    Taletrectinib
    1 Publications Verification

    DS-6051b; AB-106; IBI-344

    ROS Kinase Cancer
    Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
    Taletrectinib
  • HY-P99589

    16B5; AB-16B5

    Apoptosis Cancer
    Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
    Sotevtamab
  • HY-D0389

    Echt Brown M; AB14

    Fluorescent Dye
    Acid Brown 14 is a brown dye whose staining effects can be removed by the electrocoagulation (EC) process.
    Acid Brown 14
  • HY-131003A

    DS-6051b free base; AB-106 free base; IBI-344 free base

    ROS Kinase Cancer
    Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib free base also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
    Taletrectinib free base
  • HY-N6013

    MMP Bacterial Fungal Infection Inflammation/Immunology Cancer
    Aloin (mixture of A&B) is anthraquinone derivative isolated from Aloe vera. Aloin (mixture of A&B) has diverse biological activities such as anti-inflammatory, immunity, antidiabetic, antioxidant, antibacterial, antifungal, and antitumor activities. Aloin (mixture of A&B) also an effective inhibitor of stimulated granulocyte matrix metalloproteinases (MMPs) .
    Aloin(mixture of A&B)
  • HY-131152

    Antibiotic Infection Inflammation/Immunology
    Leucinostatin (mixture of A&B), the major components of an atypical nonapeptide complex produced by Paecilomyces lilacinus, are antibiotics .
    Leucinostatin (mixture of A&B)
  • HY-137085

    Antibiotic Fungal Infection
    Antibiotic AB023b is part of macrocyclic pentaene antibiotic complex, forming the main components with Antibiotic AB023a (HY-137084). Antibiotic AB023b exhibits antifungal activity against Candida albicans, and plant pathogenic fungi, Botrytis cinerea, Fusarium moniliforme and Pythium ultimum .
    Antibiotic AB023b
  • HY-137084

    Antibiotic Fungal Infection
    Antibiotic AB023a is part of macrocyclic pentaene antibiotic complex, forming the main components with Antibiotic AB023b (HY-137085). Antibiotic AB023a exhibits antifungal activity against Candida albicans, and plant pathogenic fungi, Botrytis cinerea (MIC= 5 μg/mL), Fusarium moniliforme and Pythium ultimum .
    Antibiotic AB023a
  • HY-122022
    JR-AB2-011
    Maximum Cited Publications
    14 Publications Verification

    mTOR Cancer
    JR-AB2-011 is a selective mTORC2 inhibitor with an IC50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (Ki: 0.19 μM) [1].JR-AB2-011 decreases the phosphorylation level of Akt, decreases MMP2 activity, thereby reducing the ability of tumor cells to migrate and invade. JR-AB2-011 also induces non-apoptotic cell death .
    JR-AB2-011
  • HY-R01634

    MicroRNA Cancer
    hsa-miR-548ab mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-548ab mimic
    hsa-miR-548ab mimic
  • HY-112142A

    DVR-23

    HBV Inflammation/Immunology
    (Rac)-AB-423 (DVR-23) is an anti-HBV candidate compound with promising anti-HBV activity. (Rac)-AB-423 showed no induction of CYP1A2, CYP3A4, or CYP2B6 enzyme activity at high concentrations. (Rac)-AB-423 exhibited desirable pharmacokinetic properties, enabling good systemic exposure and high oral bioavailability. (Rac)-AB-423 achieved more than 2 log viral load reduction in the hydrodynamic injection (HDI) HBV mouse model .
    (Rac)-AB-423
  • HY-N3026
    Soyasaponin Ab
    1 Publications Verification

    PPAR Metabolic Disease
    Soyasaponin Ab is a soyasaponin that exerts an anti-obesity effect in 3T3-L1 adipocytes through downregulation of peroxisome proliferator-activated receptor γ (PPARγ) .
    Soyasaponin Ab
  • HY-RI01634

    MicroRNA Cancer
    hsa-miR-548ab inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-548ab inhibitor
    hsa-miR-548ab inhibitor
  • HY-121986

    Solvent yellow 5

    Fluorescent Dye Others
    Yellow AB (Solvent yellow 5) is an azo dye that can be used as food dye .
    Yellow AB
  • HY-R01634A

    MicroRNA Cancer
    hsa-miR-548ab agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-548ab agomir
    hsa-miR-548ab agomir
  • HY-RS06418

    Small Interfering RNA (siRNA) Others

    HSP90AB1 Human Pre-designed siRNA Set A contains three designed siRNAs for HSP90AB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HSP90AB1 Human Pre-designed siRNA Set A
    HSP90AB1 Human Pre-designed siRNA Set A
  • HY-RS05954

    Small Interfering RNA (siRNA) Others

    H2AB1 Human Pre-designed siRNA Set A contains three designed siRNAs for H2AB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    H2AB1 Human Pre-designed siRNA Set A
    H2AB1 Human Pre-designed siRNA Set A
  • HY-RI01634A

    MicroRNA Cancer
    hsa-miR-548ab antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-548ab antagomir
    hsa-miR-548ab antagomir

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: